• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why IN8bio Is Trading Higher By 46%, Here Are 54 Stocks Moving In Tuesday's Mid-Day Session

    8/30/22 1:23:20 PM ET
    $AA
    $AHI
    $AMST
    $AMWD
    Aluminum
    Industrials
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $AA alert in real time by email

    Gainers

    • NewAge, Inc. (NASDAQ:NBEV) rose 54.4% to $0.3220.
    • IN8bio, Inc. (NASDAQ:INAB) jumped 46% to $2.89 after a Form 4 Filing showed Cavu Advisors purchased 51,214 shares at an average price of $2.02. HC Wainwright & Co. initiated coverage on IN8bio with a Buy rating and announced a price target of $14.
    • Mobile Global Esports Inc. (NASDAQ:MGAM) shares jumped 45% to $3.7705. Shares are in low-float territory; the issue has about 15 million shares in its float.
    • Forge Global Holdings, Inc. (NYSE:FRGE) gained 26.7% to $4.37.
    • Virax Biolabs Group Limited (NASDAQ:VRAX) gained 20% to $3.94.
    • American Outdoor Brands, Inc. (NASDAQ:AOUT) surged 18% to $9.17 after B. Riley upgraded the stock from Neutral to Buy and announced an $11 price target.
    • P3 Health Partners Inc. (NASDAQ:PIII) jumped 16.8% to $5.63. P3 Health Partners expanded its footprint in Nevada.
    • TMC the metals company Inc. (NASDAQ:TMC) gained 16.6% to $0.98. The company recently posted a quarterly loss of $0.05 per share.
    • OKYO Pharma Limited (NASDAQ:OKYO) gained 15.9% to $2.33. OKYO Pharma plans Q4 IND filing of OK-101 to treat dry eye disease with subsequent Phase 2 initiation.
    • FaZe Holdings Inc. (NASDAQ:FAZE) gained 14% to $19.37.
    • Hour Loop, Inc. (NASDAQ:HOUR) jumped 13.7% to $3.7300.
    • American Woodmark Corporation (NASDAQ:AMWD) gained 13.2% to $53.72 after reporting better-than-expected Q1 results.
    • Barfresh Food Group, Inc. (NASDAQ:BRFH) rose 12.1% to $3.81.
    • Avid Technology, Inc. (NASDAQ:AVID) gained 11.7% to $26.96. Avid Technology will replace Plantronics in the S&P SmallCap 600 on Thursday, September 1.
    • Check-Cap Ltd. (NASDAQ:CHEK) rose 11.4% to $0.4598 after gaining over 4% on Monday.
    • ECMOHO Limited (NASDAQ:MOHO) rose 11.4% to $0.1637.
    • Arco Platform Limited (NASDAQ:ARCE) gained 10% to $14.57. JP Morgan upgraded Arco Platform from Neutral to Overweight and lowered the price target from $21 to $20.
    • Sharps Technology, Inc. (NASDAQ:STSS) rose 7.9% to $1.50.
    • Blue Water Vaccines, Inc. (NASDAQ:BWV) shares gained 5.6% to $3.01 after a 13D Filing showed Cincinnati Cornerstone Investors reported a 22.9% stake in the company.
    • Big Lots, Inc. (NYSE:BIG) surged 4.8% to $22.58 after the company reported a second-quarter FY22 sales decline of 7.6% year-on-year to $1.346 billion, marginally beating the consensus of $1.34 billion. Comparable sales decreased 9.2%.


    Losers

    • Amesite Inc. (NASDAQ:AMST) shares dropped 46.4% to $0.4458 after the company announced a $2.3 million registered direct offering.
    • Baudax Bio, Inc. (NASDAQ:BXRX) shares fell 40% to $0.3275 after the company reported pricing of $6.2 million public offering.
    • Liquidia Corporation (NASDAQ:LQDA) declined 28.3% to $5.54.
    • Jianzhi Education Technology Group Company Limited (NASDAQ:JZ) fell 26.5% to $6.15 on profit-taking after the stock surged following its IPO.
    • Sentage Holdings Inc. (NASDAQ:SNTG) shares dipped 26% to $3.70 on possible profit taking after the stock surged Monday.
    • The OLB Group, Inc. (NASDAQ:OLB) fell 25% to $1.50.
    • Photronics, Inc. (NASDAQ:PLAB) fell 23% to $16.76. Photronics posted upbeat Q3 results, but issued weak outlook for the current quarter.
    • Advanced Human Imaging Limited (NASDAQ:AHI) fell 21.3% to $1.0394. Advanced Human Imaging shares jumped 94% on Monday after the company announced it signed a Master Services Agreement with Activate Health OÜ.
    • Starbox Group Holdings Ltd. (NASDAQ:STBX) declined 21.1% to $5.08 as the stock sees volatility following its IPO last Tuesday.
    • Cabaletta Bio, Inc. (NASDAQ:CABA) dropped 17.9% to $1.03. Morgan Stanley downgraded Cabaletta Bio from Overweight to Equal-Weight and lowered the price target from $15 to $3.
    • Veru Inc. (NASDAQ:VERU) fell 17.8% to $13.56.
    • Cross Timbers Royalty Trust (NYSE:CRT) fell 17.8% to $20.23. Shares of several energy companies traded lower as the sector pulls back from recent gains amid raised concerns of aggressive interest rates hikes, which could pressure oil demand.
    • Azure Power Global Limited (NYSE:AZRE) dropped 17.5% to $4.83 after Credit Suisse downgraded the stock from Outperform to Underperform and lowered its price target from $22 to $5.
    • Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) fell 17.5% to $0.1295. Clarus Therapeutics shares dipped 23% on Monday after the company announced it has received a non-compliance letter from Nasdaq. The shares will be suspended on August 31st and will begin trading on the OTC Pink Market.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) dropped 17.5% to $1.1550.
    • Bright Minds Biosciences Inc. (NASDAQ:DRUG) declined 17.3% to $2.4389.
    • Jounce Therapeutics, Inc. (NASDAQ:JNCE) dropped 16.8% to $3.5650 after the company reported top line data from Phase 2 SELECT trial evaluating Vopratelimab.
    • ZeroFox Holdings, Inc. (NASDAQ:ZFOX) fell 16.8% to $5.49.
    • Indonesia Energy Corporation Limited (NASDAQ:INDO) dropped 16.6% to $7.64.
    • Onfolio Holdings, Inc. (NASDAQ:ONFO) declined 16.1% to $1.8450. The company recently priced its IPO at $5 per unit.
    • Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) declined 14.9% to $0.1968. Ladenburg Thalmann recently initiated coverage on the stock with a Buy rating and announced a price target of $6.50.
    • BrainsWay Ltd. (NASDAQ:BWAY) fell 14% to $4.0001. The FDA, on Monday, granted 510(k) clearance to BrainsWay Ltd's (NASDAQ:BWAY) Deep Transcranial Magnetic Stimulation (TMS) H7 Coil for its use in treating adults suffering from major depressive disorder and depression, including those with comorbid anxiety symptoms commonly known as anxious depression.
    • REX American Resources Corporation (NYSE:REX) dropped 13.9% to $28.95. The company reported upbeat quarterly earnings.
    • Silver Crest Acquisition Corporation (NASDAQ:SLCR) fell 12.5% to $8.88.
    • Plus Therapeutics, Inc. (NASDAQ:PSTV) dipped 12.5% to $0.8750.
    • Houston American Energy Corp. (NYSE:HUSA) dropped 11.9% to $4.37.
    • Melco Resorts & Entertainment Limited (NASDAQ:MLCO) fell 10.6% to $5.43.
    • Marpai, Inc. (NASDAQ:MRAI) fell 9.8% to $0.9198.
    • iQIYI, Inc. (NASDAQ:IQ) declined 9% to $3.5750 after the company reported Q2 earnings results.
    • Alcoa Corporation (NYSE:AA) dropped 8.6% to $50.71. Alcoa to curtail one third of production capacity at Lista Smelter in Norway to mitigate high energy costs.
    • Nikola Corporation (NASDAQ:NKLA) fell 8.1% to $5.49 after the company filed a prospectus related to the issuance and sale of common stock from time to time up to $400 million. The company also announced an exchange offer to purchase all outstanding shares of Romeo Power.
    • Helmerich & Payne, Inc. (NYSE:HP) dropped 6.6% to $42.43. Shares of several energy companies traded lower as the sector pulls back from recent gains amid raised concerns of aggressive interest rates hikes, which could pressure oil demand.
    • Baidu, Inc. (NASDAQ:BIDU) declined 6.3% to $138.06 after the company reported Q2 EPS results.
    • Cuentas Inc. (NASDAQ:CUEN) fell 5.7% to $0.68. Cuentas shares gained over 5% on Monday after the company announced it has entered into a collaboration for exclusive licensing and transaction sharing with The OLB Group to upgrade the company's Bodega network and help them evolve into financial centers.
    Get the next $AA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AA
    $AHI
    $AMST
    $AMWD

    CompanyDatePrice TargetRatingAnalyst
    Bright Minds Biosciences Inc.
    $DRUG
    4/13/2026$145.00Buy
    Jefferies
    Alcoa Corporation
    $AA
    4/9/2026$80.00Equal-Weight → Overweight
    Morgan Stanley
    Baidu Inc. ADS
    $BIDU
    4/1/2026$161.00Outperform
    BNP Paribas Exane
    Photronics Inc.
    $PLAB
    3/20/2026$46.00Buy
    Lake Street
    Helmerich & Payne Inc.
    $HP
    3/20/2026$43.00In-line → Outperform
    Evercore ISI
    Alcoa Corporation
    $AA
    3/13/2026$68.00Underweight → Neutral
    Analyst
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    Melco Resorts & Entertainment Limited
    $MLCO
    2/17/2026$9.50Neutral → Buy
    UBS
    More analyst ratings

    $AA
    $AHI
    $AMST
    $AMWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Bright Minds Biosciences with a new price target

    Jefferies initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $145.00

    4/13/26 8:51:07 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alcoa upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Alcoa from Equal-Weight to Overweight and set a new price target of $80.00

    4/9/26 8:21:40 AM ET
    $AA
    Aluminum
    Industrials

    BNP Paribas Exane initiated coverage on Baidu with a new price target

    BNP Paribas Exane initiated coverage of Baidu with a rating of Outperform and set a new price target of $161.00

    4/1/26 8:26:04 AM ET
    $BIDU
    Computer Software: Programming Data Processing
    Technology

    $AA
    $AHI
    $AMST
    $AMWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Daniels Eric Joseph

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    4/22/26 5:00:04 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Zhang Rui

    4 - PHOTRONICS INC (0000810136) (Issuer)

    4/21/26 8:47:04 PM ET
    $PLAB
    Semiconductors
    Technology

    SEC Form 4 filed by Paladino Mary

    4 - PHOTRONICS INC (0000810136) (Issuer)

    4/21/26 8:44:47 PM ET
    $PLAB
    Semiconductors
    Technology

    $AA
    $AHI
    $AMST
    $AMWD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cuentas Inc. Reports 2025 Strategic Transformation, Cuts Annual Net Loss by more than 50%, Streamlines Legacy Liabilities, and Expands World Mobile Alliance

    Miami Beach, FL, April 23, 2026 (GLOBE NEWSWIRE) -- Cuentas Inc. (OTCQB:CUEN) today announced a pivotal year of strategic transformation in connection with its Annual Report on Form 10-K for the year ended December 31, 2025, highlighted by a reduction in annual net loss of 52.5%, significant progress in resolving legacy liabilities, and continued expansion of its high-potential alliance with World Mobile Group Ltd. During 2025, Cuentas sharpened its focus around its mobile communications platform and executed a series of transactions designed to strengthen its operating foundation, simplify its balance sheet, and accelerate long-term strategic positioning. The Company believes these acti

    4/23/26 8:27:11 AM ET
    $CUEN
    Computer Software: Prepackaged Software
    Technology

    Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

    HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced today the initiation of manufacturing activities and technology transfer with SpectronRx under a previously executed Master Services Agreement (MSA), in support of late-stage clinical manufacturing of Rhenium-186 and REYOBIQ. With SpectronRx serving as a second GMP manufacturing site alongside Radiomedix, and Rhenium-186 isotope supplied through Telix Pharmaceuticals, Plus strengthens the reliability of its multi-partner supply chain

    4/23/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Baidu to Report First Quarter 2026 Financial Results on May 18, 2026

    BEIJING, April 23, 2026 /PRNewswire/ -- Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) ("Baidu" or the "Company"), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the First Quarter 2026 ended March 31, 2026, before the U.S. market opens on May 18, 2026. Baidu's management will hold an earnings conference call at 8:00 AM on May 18, 2026, U.S. Eastern Time (8:00 PM on May 18, 2026, Beijing Time). Please register in advance of the conference call using the link provided below. It will automatically direct you to the registration page of "Baidu Inc. Q1 2026 Earnings Conference Call". Please follow t

    4/23/26 5:00:00 AM ET
    $BIDU
    Computer Software: Programming Data Processing
    Technology

    $AA
    $AHI
    $AMST
    $AMWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AA
    $AHI
    $AMST
    $AMWD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $AA
    $AHI
    $AMST
    $AMWD
    SEC Filings

    View All

    Chief Medical Officer Chang David J. bought $19,888 worth of shares (8,800 units at $2.26) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:58 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President, Science & Tech. Binder Gwendolyn bought $24,763 worth of shares (11,312 units at $2.19), increasing direct ownership by 57% to 31,312 units (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:30 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Tomasello Shawn bought $50,322 worth of shares (22,725 units at $2.21) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:55:49 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for ENTADFI issued to VERU INC

    Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

    12/13/21 8:12:46 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

    Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form

    11/18/21 2:49:33 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Melco Resorts & Entertainment Limited

    6-K - Melco Resorts & Entertainment LTD (0001381640) (Filer)

    4/24/26 6:30:11 AM ET
    $MLCO
    Hotels/Resorts
    Consumer Discretionary

    Mobile Global Esports Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Mobile Global Esports, Inc. (0001886362) (Filer)

    4/23/26 9:23:24 PM ET
    $MGAM
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form DEFA14A filed by Barfresh Food Group Inc.

    DEFA14A - BARFRESH FOOD GROUP INC. (0001487197) (Filer)

    4/23/26 5:51:38 PM ET
    $BRFH
    Packaged Foods
    Consumer Staples

    $AA
    $AHI
    $AMST
    $AMWD
    Financials

    Live finance-specific insights

    View All

    Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

    HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced today the initiation of manufacturing activities and technology transfer with SpectronRx under a previously executed Master Services Agreement (MSA), in support of late-stage clinical manufacturing of Rhenium-186 and REYOBIQ. With SpectronRx serving as a second GMP manufacturing site alongside Radiomedix, and Rhenium-186 isotope supplied through Telix Pharmaceuticals, Plus strengthens the reliability of its multi-partner supply chain

    4/23/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Baidu to Report First Quarter 2026 Financial Results on May 18, 2026

    BEIJING, April 23, 2026 /PRNewswire/ -- Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) ("Baidu" or the "Company"), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the First Quarter 2026 ended March 31, 2026, before the U.S. market opens on May 18, 2026. Baidu's management will hold an earnings conference call at 8:00 AM on May 18, 2026, U.S. Eastern Time (8:00 PM on May 18, 2026, Beijing Time). Please register in advance of the conference call using the link provided below. It will automatically direct you to the registration page of "Baidu Inc. Q1 2026 Earnings Conference Call". Please follow t

    4/23/26 5:00:00 AM ET
    $BIDU
    Computer Software: Programming Data Processing
    Technology

    iQIYI to Report First Quarter 2026 Financial Results on May 18, 2026

    BEIJING, April 23, 2026 (GLOBE NEWSWIRE) -- iQIYI, Inc. (NASDAQ:IQ) ("iQIYI" or the "Company"), a leading provider of online entertainment video services in China, today announced that it will report its financial results for the first quarter ended March 31, 2026 before the U.S. market opens on May 18, 2026. iQIYI's management will hold an earnings conference call at 7:00 AM on May 18, 2026, U.S. Eastern Time (7:00 PM on May 18, 2026, Beijing Time). Please register in advance of the conference using the link provided below. Upon registering, you will be provided with participant dial-in numbers, passcode and unique access PIN by a calendar invite. Participant Online Registration: https

    4/23/26 5:00:00 AM ET
    $IQ
    Consumer Electronics/Video Chains
    Consumer Discretionary

    $AA
    $AHI
    $AMST
    $AMWD
    Leadership Updates

    Live Leadership Updates

    View All

    Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that it has granted inducement awards to Eric J Daniels, M.D., its new Chief Development Officer who joined the Company on April 20, 2026. The awards were granted on April 20, 2026 under the Company's 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist of options to purchase 20,000 shares of the Company common

    4/22/26 4:30:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

    HOUSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of Randy H. Goodman, Ph.D., M.H.A., as Vice President, Value Strategy & Health Economics and Outcomes Research (HEOR), effective April 13th, 2026. Dr. Goodman is a highly experienced health economics and market access leader with more than 20 years of experience spanning global pricing and reimbursement strategy, real-world evidence generation, and value-based healthcare modeling across the biotechnology, pharmaceutic

    4/15/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

    HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the appointment of Eric J. Daniels, M.D., MBA, as Chief Development Officer, effective April 20, 2026. Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development. He most recently served as Chief Development Officer at Kiora Pharmaceuticals , where he oversaw the company's full development portfolio

    4/9/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $AA
    $AHI
    $AMST
    $AMWD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/5/24 4:50:19 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care